Wilson Petrushnko1, Justin S Gundara1, Philip R De Reuver1, Greg O'Grady2, Jaswinder S Samra1, Anubhav Mittal3. 1. Upper Gastrointestinal Surgical Unit, Royal North Shore Hospital, North Shore Private Hospital, University of Sydney, St Leonards, NSW 2065, Australia. 2. Department of Surgery, University of Auckland, New Zealand. 3. Upper Gastrointestinal Surgical Unit, Royal North Shore Hospital, North Shore Private Hospital, University of Sydney, St Leonards, NSW 2065, Australia. Electronic address: anubhav.mittal@sydney.edu.au.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) continues to be associated with a poor prognosis. This systematic review aimed to summarize the literature regarding potential prognostic biomarkers to facilitate validation studies and clinical application. METHODS: A systematic review was performed (2004-2014) according to PRISMA guidelines. Studies were ranked using REMARK criteria and the following outcomes were examined: overall/disease free survival, nodal involvement, tumour characteristics, metastasis, recurrence and resectability. RESULTS: 256 biomarkers were identified in 158 studies. 171 biomarkers were assessed with respect to overall survival: urokinase-type plasminogen activator receptor, atypical protein kinase C and HSP27 ranked the highest. 33 biomarkers were assessed for disease free survival: CD24 and S100A4 were the highest ranking. 17 biomarkers were identified for lymph node involvement: Smad4/Dpc4 and FOXC1 ranked highest. 13 biomarkers were examined for tumour grade: mesothelin and EGFR were the highest ranking biomarkers. 10 biomarkers were identified for metastasis: p16 and sCD40L were the highest ranking. 4 biomarkers were assessed resectability: sCD40L, s100a2, Ca 19-9, CEA. CONCLUSION: This review has identified and ranked specific biomarkers that should be a primary focus of ongoing validation and clinical translational work in PDAC.
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) continues to be associated with a poor prognosis. This systematic review aimed to summarize the literature regarding potential prognostic biomarkers to facilitate validation studies and clinical application. METHODS: A systematic review was performed (2004-2014) according to PRISMA guidelines. Studies were ranked using REMARK criteria and the following outcomes were examined: overall/disease free survival, nodal involvement, tumour characteristics, metastasis, recurrence and resectability. RESULTS: 256 biomarkers were identified in 158 studies. 171 biomarkers were assessed with respect to overall survival: urokinase-type plasminogen activator receptor, atypical protein kinase C and HSP27 ranked the highest. 33 biomarkers were assessed for disease free survival: CD24 and S100A4 were the highest ranking. 17 biomarkers were identified for lymph node involvement: Smad4/Dpc4 and FOXC1 ranked highest. 13 biomarkers were examined for tumour grade: mesothelin and EGFR were the highest ranking biomarkers. 10 biomarkers were identified for metastasis: p16 and sCD40L were the highest ranking. 4 biomarkers were assessed resectability: sCD40L, s100a2, Ca 19-9, CEA. CONCLUSION: This review has identified and ranked specific biomarkers that should be a primary focus of ongoing validation and clinical translational work in PDAC.
Authors: Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad Journal: Ann Surg Oncol Date: 2013-02-23 Impact factor: 5.344
Authors: John J Liang; Hua Wang; Asif Rashid; Tse-Hua Tan; Rosa F Hwang; Stanley R Hamilton; James L Abbruzzese; Douglas B Evans; Huamin Wang Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Andrew V Biankin; James G Kench; Emily K Colvin; Davendra Segara; Christopher J Scarlett; Nam Q Nguyen; David K Chang; Adrienne L Morey; C-Soon Lee; Mark Pinese; Samuel C L Kuo; Johana M Susanto; Peter H Cosman; Geoffrey J Lindeman; Jane E Visvader; Tuan V Nguyen; Neil D Merrett; Janindra Warusavitarne; Elizabeth A Musgrove; Susan M Henshall; Robert L Sutherland Journal: Gastroenterology Date: 2009-04-16 Impact factor: 22.682
Authors: Felix C Popp; Marie Christine Popp; Yue Zhao; Christopher Betzler; Siegfried Kropf; Benjamin Garlipp; Christoph Benckert; Thomas Kalinski; Hans Lippert; Christiane J Bruns Journal: BMC Cancer Date: 2017-03-29 Impact factor: 4.430
Authors: Willemieke S Tummers; Arantza Farina-Sarasqueta; Martin C Boonstra; Hendrica A Prevoo; Cornelis F Sier; Jan S Mieog; Johannes Morreau; Casper H van Eijck; Peter J Kuppen; Cornelis J van de Velde; Bert A Bonsing; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg Journal: Oncotarget Date: 2017-05-26
Authors: C Mattevi; J Garnier; U Marchese; J Ewald; M Gilabert; F Poizat; G Piana; J R Delpero; O Turrini Journal: BMC Surg Date: 2020-08-05 Impact factor: 2.102